ProAssurance Shareholders Await Final Chapter as Acquisition Nears Completion

ProAssurance US74267C1062

The planned acquisition of U.S. specialty insurer ProAssurance is moving into its final stages. Shareholders are set to receive a cash payment of $25.00 per share as the company prepares to conclude its independence. The deal, valued at approximately $1.3 billion, was initially announced in March 2025 by the acquiring entity, The Doctors Company, and is on track to close in the first half of 2026.

Key Deal Terms:
* Acquiring Entity: The Doctors Company
* Offer Price: $25.00 per share in cash
* Total Transaction Value: Roughly $1.3 billion
* Expected Closing Window: First half of 2026
* Post-Deal Status: Shares will be delisted from the New York Stock Exchange (NYSE)

Significant regulatory milestones for the merger have already been achieved. The U.S. Federal Trade Commission (FTC) concluded the mandatory waiting period under the Hart-Scott-Rodino Act ahead of schedule in July of last year. This clearance has effectively removed the major obstacles to integrating ProAssurance as a wholly-owned subsidiary. Pending the satisfaction of standard closing conditions, the company's stock will subsequently be removed from listing on the NYSE.

Forging a Market Leader in Medical Liability

The union of these two firms is poised to create a dominant force in the U.S. medical professional liability insurance sector. The combined organization will manage assets totaling around $12 billion. Commanding an estimated market share nearing 16%, the new entity will establish itself as a principal provider for physicians, hospitals, and medical technology companies across the nation.

As ProAssurance approaches its final days as a publicly traded company, investors are looking ahead to February 23. On this date, the insurer is scheduled to release its financial results for the fourth quarter of 2025. The report is also anticipated to provide shareholders with an update on the remaining steps toward finalizing the merger.